Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.2 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs Limited has submitted its audited standalone and consolidated financial results for the quarter ended June 30, 2025 (Q1 FY26), approved by the Board on July 18, 2025. Statutory auditor Gokhale & Sathe issued an unqualified (clean) opinion on both the standalone and consolidated results, stating they present a true and fair view in line with Ind AS-34. Consolidated results cover subsidiaries Pinnacle Life Science, Aarti Specialty Chemicals, and the foreign subsidiary Pinnacle Chilre Pharma Go SpA. Separately, the Board appointed M/s. Mehta & Mehta as Secretarial Auditors for a five-year term (FY2025-26 to FY2029-30), subject to shareholder approval at the next AGM, in line with SEBI's recent listing regulation amendments. Detailed line-item financials are not clearly legible in the filing copy provided.
This is a routine quarterly compliance filing with a clean audit opinion, suggesting no immediate red flags for shareholders. The secretarial auditor appointment is procedural and required under updated SEBI regulations, so it should not materially affect the stock.